Table 2.

Univariable and multivariable analyses for PFS

LabelModalityUnivariableMultivariable
HR95% CIPHR95% CIP
IPI 3-5 1.8 1.1-3.1 .0195    
TMTV >220 2.3 1.5-3.5 .0002 2.1 1.3-3.2 .0018 
Treatment arm Lenalidomide 0.6 0.4-0.9 .0152 0.6 0.4-0.9 .0486 
NCCN-IPI score High-intermediate 2.0 1.0-3.9 .035    
High 1.4 0.8-2.3 .22    
ECOG PS ≥2 2.3 1.4-3.7 .0004 2.0 1.2-3.3 .0044 
Ann Arbor stage III-IV 2.0 0.8-4.9 .13    
LDH level Elevated 1.2 0.8-1.8 .53    
β2 microglobulin ≥3 mg/L 1.3 0.8-2.1 .23    
Albumin >35 g/L 0.7 0.4-1.1 .08    
Time to treatment (days)  1.0 0.99-1.0 .53    
LabelModalityUnivariableMultivariable
HR95% CIPHR95% CIP
IPI 3-5 1.8 1.1-3.1 .0195    
TMTV >220 2.3 1.5-3.5 .0002 2.1 1.3-3.2 .0018 
Treatment arm Lenalidomide 0.6 0.4-0.9 .0152 0.6 0.4-0.9 .0486 
NCCN-IPI score High-intermediate 2.0 1.0-3.9 .035    
High 1.4 0.8-2.3 .22    
ECOG PS ≥2 2.3 1.4-3.7 .0004 2.0 1.2-3.3 .0044 
Ann Arbor stage III-IV 2.0 0.8-4.9 .13    
LDH level Elevated 1.2 0.8-1.8 .53    
β2 microglobulin ≥3 mg/L 1.3 0.8-2.1 .23    
Albumin >35 g/L 0.7 0.4-1.1 .08    
Time to treatment (days)  1.0 0.99-1.0 .53    
View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal